Immunohistochemical characterization of inflammatory and proliferative events during chronic rejection in rat lung allografts

Transplantation

Volumn 64, Issue 3, 1997, Pages 465-471

  Lee, Allan G L ^a   Wagner, Florian M ^a   Giaid, Adel ^b   Chen, Moy Fong ^b   Hamid, Qutayba ^b   Serrick, Cyril ^a   Shennib, Hani ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 8;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GRAFT REJECTION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LUNG TRANSPLANTATION; MALE; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; BIOPSY; BRONCHIOLITIS OBLITERANS; CHRONIC DISEASE; GRAFT REJECTION; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; MALE; RATS; RATS, INBRED BN; RATS, INBRED LEW; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030855308     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199708150-00016     Document Type: Article

References (27)

1. Hosenpud JD, Novick RJ, Breen TJ, et al. The registry of the International Society for Heart and Lung Transplantation: twelfth official report - 1995. J Heart Lung Transplant 1995; 14: 805.
2. Reichenspurner H, Girgis RE, Robbins RC, et al. Obliterative bronchiolitis after lung and heart-lung transplantation. Ann Thorac Surg 1995; 60: 1845.
3. Al-Dossari GA, Jessurun J, Bolman RM III, et al. Pathogenesis of obliterative bronchiolitis: possible roles of platelet-derived growth factor and basic fibroblast growth factor. Transplantation 1995; 59: 143.
4. Wu CJ, Lovett M, Wong-Lee J, et al. Cytokine gene expression in rejecting cardiac allografts. Transplantation 1992; 54: 326.
5. Migliori RJ, Gruber SA, Hoffman RA, Ascher NL, Simmons RL. Recombinant products of macrophage activation can attract circulating lymphocytes in vivo. Surg Forum 1987; 38: 350.
6. Fanslow WC, Sims JE, Sassenfield H, et al. Regulation of alloreactivity in vivo by a soluble form of interleukin-1 receptor. Science 1990; 248: 739.
7. Strieter RM, Standiford TJ, Rolfe MW, Kunkel SL. Interleukin-8. In: Kelly J, ed. Lung biology in health and disease: cytokines of the lung. New York: Marcel Dekker, 1993: 281.
8. Thomas KA, Gimenez-Gallego G. Pure brain-derived acidic fibroblast growth factor is a potent angiogenic vascular endothelial cell mitogen with sequence homology to interleukin-1. Proc Natl Acad Sci USA 1985; 82: 6409.
9. Slavin J. Fibroblast growth factors at the heart of angiogenesis. Cell Biol Int 1995; 19: 431.
10. Reis A, Giaid A, Serrick C, Shennib H. Improved outcome of rat lung transplantation with modification of the nonsuture external cuff technique. J Heart Lung Transplant 1995; 14: 274.
11. Uyama T, Winter JB, Groen G, et al. Late airway changes caused by chronic rejection in rat lung allografts. Transplantation 1992; 54: 809.
12. Al-Dossari GA, Kshettery VR, Jessurun J, Bolman RM III. Experimental large- animal model of obliterative bronchiolitis after lung transplantation. Ann Thorac Surg 1994; 58: 34.
13. Scott JP, Higgenbottam TW, Sharples L, et al. Risk factors for obliterative bronchiolitis in heart-lung transplant recipients. Transplantation 1991; 51: 813.
14. Paradis I, Yousem SA, Griffith B. Airway obstruction and bronchiolitis obliterans after lung transplantation. Clin Chest Med 1993; 14: 751.
15. Winter JB, Gouw ANS, Groen M, et al. Respiratory viral infections aggravate airway damage caused by chronic rejection in rat lung allografts. Transplantation 1994; 57: 418.
16. Serrick C, Adoumie R, Giaid A, et al. The early release of interleukin-2, tumor necrosis factor-alpha and interferon-gamma after ischemia reperfusion injury in the lung allograft. Transplantation 1994; 58: 1158.
17. Milne DS, Gascoigne AD, Ashcroft T, et al. Organizing pneumonia following pulmonary transplantation and the development of obliterative bronchiolitis. Transplantation 1994; 57: 1757.
18. Reid KR, McKenzie FN, Menkis AH, et al. Importance of chronic aspiration in recipients of heart-lung transplants. Lancet 1990; 336: 206.
19. Matsumura Y, Marchevsky A, Zuo XJ, et al. Assessment of pathological changes associated with chronic allograft rejection and tolerance in two experimental models of rat lung transplantation. Transplantation 1995; 59: 1509.
20. Shennib H. Chronic irreversible graft dysfunction (CIGD) and animal models of obliterative bronchiolitis. In: Shennib H, ed. Medical intelligence unit: immunology of the lung allograft. Austin: RG Landes Company, 1995: 121.
21. Hertz MI, Jessurun J, King MB, Kay Savik S, Murray JJ. Reproduction of the obliterative bronchiolitis lesion after heterotopic transplantation of mouse airways. Am J Pathol 1993; 142: 1945.
22. Elias JA, Freundlich B, Kern JA, Rosenbloom J. Cytokine networks in the regulation of inflammation and fibrosis in the lung. Chest 1990; 97: 1439.
23. Hertz MI, Henke CA, Nakhleh RE, et al. Obliterative bronchiolitis after lung transplantation: a fibroproliferative growth factor associated with platelet-derived growth factor. Proc Natl Acad Sci USA 1992; 89: 10385.
24. Coupes BM, Newstead CG, Short CD, Brenchly PEC. Transforming growth factor β1 in renal allograft recipients. Transplantation 1994; 57: 1727.
25. Giaid A, Saleh D, Yanagisawa M, Forbes RDC. Endothelin-1 immunoreactivity and mRNA in the transplanted human heart. Transplantation 1995; 59: 1308.
26. Shennib H, Serrick C, Saleh D, et al. Alterations in bronchoalveolar lavage and plasma endothelin-1 levels early after lung transplantation. Transplantation 1995; 59: 994.
27. Shennib H, Serrick C, Saleh D, et al. Plasma endothelin-1 levels in human lung transplant recipients. J Cardiovasc Pharmacol 1995; 26 (suppl): S516.